 "Sun Pharma settles Absorica patent litigation suit with Actavis in US")
Don't want to miss the best from Business Standard?
Ranbaxy Pharmaceuticals Inc, a wholly-owned subsidiary of Sun Pharmaceutical, along with its partners, Cipher Pharmaceuticals Inc and Galephar Pharmaceutical Research Inc, have entered into a settlement agreement with Actavis Group that dismisses the patent litigation suit relating to Actavis’ abbreviated new drug application (ANDA) for a generic version of Absorica (isotretinoin capsules).
Absorica, which is the registered trademark of Ranbaxy Laboratories, is prescribed for treatment of the most severe form of acne (nodular acne).
As part of the settlement agreement, Ranbaxy, Cipher and Galephar have entered into a non-exclusive license agreement with Actavis under which Actavis may begin selling its generic version of Absorica in the US on December 27, 2020 (approximately nine months prior to the expiration of the patents in September 2021) or earlier under certain circumstances.
The settlement agreement is subject to review by the US Federal Trade Commission (FTC) and the US Department of Justice.
Absorica, which is the registered trademark of Ranbaxy Laboratories, is prescribed for treatment of the most severe form of acne (nodular acne).
As part of the settlement agreement, Ranbaxy, Cipher and Galephar have entered into a non-exclusive license agreement with Actavis under which Actavis may begin selling its generic version of Absorica in the US on December 27, 2020 (approximately nine months prior to the expiration of the patents in September 2021) or earlier under certain circumstances.
The settlement agreement is subject to review by the US Federal Trade Commission (FTC) and the US Department of Justice.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%